Physician profile
Maci A Kelley
NPI 1942962519
$3,558.64
in general payments reported to CMS, 2019-2025
32 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.18 · 2022: $873 · 2023: $365 · 2024: $1,069 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,608.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $775.73 | 2022-2025 | |
| Novo Nordisk INC | $560.94 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $452.40 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $238.17 | 2022-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $155.22 | 2022-2025 | Caplyta |
| Pfizer INC. | $149.64 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $141.31 | 2022-2025 | Airsupra |
| Lilly USA, LLC | $133.19 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Exact Sciences Corporation | $111.88 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.11 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $99.59 | 2021-2024 | |
| Amgen INC. | $72.10 | 2022-2025 | Repatha, Otezla, Repatha |
| Vanda Pharmaceuticals INC. | $64.58 | 2024-2025 | Fanapt, Hetlioz |
| Xeris Pharmaceuticals, INC. | $56.03 | 2023-2025 | Gvoke Hypopen |
| Ucb, INC. | $36.70 | 2024 | Briviact |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.69 | 2024-2025 | Xifaxan |
| Ardelyx, INC. | $36.57 | 2024 | Ibsrela |
| Axsome Therapeutics, INC. | $34.51 | 2024-2025 | Auvelity |
| Lundbeck LLC | $34.18 | 2025 | Rexulti |
| Mylan Specialty L.P. | $31.26 | 2021-2024 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $29.65 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.59 | 2021 | |
| Sunovion Pharmaceuticals INC. | $21.54 | 2022 | |
| Dexcom, INC. | $21.42 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $20.56 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $20.51 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $18.34 | 2023 | Eliquis |
| Tactile Systems Technology INC | $18.31 | 2023 | Flexitouch Plus, Entre Plus |
| Viatris Specialty LLC | $14.78 | 2025 | Yupelri |
| Astellas Pharma US INC | $14.43 | 2023 | Veozah |
| Arbor Pharmaceuticals, INC. | $14.36 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maci Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.